| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/04/2026 | ±2.2% | +1.5% | over-priced |
| 05/05/2026 | ±2.3% | +0.6% | over-priced |
| 11/04/2025 | ±1.8% | -1.5% | over-priced |
| 08/05/2025 | ±2.0% | +5.2% | under-priced |
| 05/05/2025 | ±3.0% | -1.4% | over-priced |
| 11/04/2024 | ±2.0% | -1.2% | over-priced |
| 08/05/2024 | ±3.5% | -2.3% | over-priced |
| 05/08/2024 | ±3.3% | +1.8% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $-0.04 | $15.0B | $-237M |
| Q1 FY2026 | $0.47 | $14.5B | $2.7B |
| Q4 FY2025 | $-0.29 | $17.6B | $-1.6B |
| Q3 FY2025 | $0.62 | $16.7B | $3.5B |
Pfizer Inc. (PFE) reports in 75 days, with the next report estimated for 11/26/2026. Across the last 8 reports, options priced an average ±2.5% earnings move while the stock actually moved 1.9% on average — the market has systematically over-priced PFE's earnings risk. Fundamentals into the print: EPS down 107.8% year-over-year, revenue up 2.6%. QuantLogix's live 5-factor engine currently reads PFE as a buy at 65/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →